- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05919667
Dairy and Non-Dairy Alternatives Comparative on Metabolic Outcomes
The Effects of Dairy and Non-Dairy Alternatives on Glycemic and Appetite Regulation in Healthy Young Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the past forty years, the prevalence of obesity in adults has doubled with nearly two thirds of Canadian adults currently overweight or obese. The global epidemic of obesity also makes certain individuals more vulnerable to common co-morbidities of obesity, such as type-2-diabetes. To combat these rising numbers, Health Canada released a new Canadian Food Guide (CFG) in 2019. One particular alteration to the new CFG includes dietary guidelines encouraging for an increased consumption of plant-based foods as protein rich sources, shifting away from the promotion of animal-based food products, such as dairy. However, many of the available plant-based substitutes in the market are highly processed with high amounts of sugar, fat, sodium, and additives compared to animal-based products. While literature has shown for plant-based foods to confer numerous health benefits, these are often plant-based foods that have been unprocessed, except for cooking. As the demand for plant-based products continues to grow annually, it is important to assess and compare various obesity and T2D related metabolic outcomes, such as glycemic regulation and appetite control, to better understand the physiological functionality of these products and what role they may or may not play in mitigating the obesity and T2D global epidemics. There is a growing body of evidence from clinical and meta-analysis trials that show dairy products reduce satiety and provide better glycemic control; highlighting their potential to help reduce risk factors associated with obesity and T2D. However, literature has mainly focused on nutrient profile or isolated protein comparatives between animal and plant-based sources. Instead, this study will be looking at comparing dairy products and their plant-based counterparts with respect to their food matrix as a whole, to understand what responses these products produce in the form consumers are naturally eating them by. This study will focus on assessing the metabolic outcomes related to satiety and glycemic regulation. Satiety is an important physiological function related to food intake, and thus, provides a measure to assess reduced obesity risk. Additionally, postprandial glycemic control is an important physiological function that is not only related to the development of type-2 diabetes but also satiety.
A total of 16 participants (8 males and 8 females) will participate in this study at the University of Toronto.
The study will include a total of 5 sessions over the span of 5 weeks. Prior to the visit, participants will be fasted for 12 hours, excluding water for up to 1 hour before the study visit. During each session, participants will consume a dairy product or a non-dairy plant-based product while subjective appetite, blood glucose, insulin, C-peptide, and gut hormones (ghrelin, GLP-1, GLP-2, and GIP) are obtained post-treatment at 20 min and post a secondary fixed meal of pasta within 15-30 min intervals over a 2 hour timespan. Plasma amino acid concentrations will also be measured within the same timeline outlined above.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5S 3H2
- Department of Nutritional Sciences, C. David Naylor Building
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI: ≥18.5 kg/m2 and ≤ 24.5 kg/m2'
- Fasting serum glucose: ≤ 5.5 mmol/L
- Frequent breakfast consumers
- Willing to maintain habitual diet, physical activity pattern, dietary supplement routine, and body weight throughout the trial
- Willing to abstain from alcohol consumption for 24 h prior to all test visits.
- Willing to avoid vigorous physical activity for 24 h prior to all test visits.
- Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.
Exclusion Criteria:
- Fasting blood glucose > 5.5 mmol/L
- Smoking tobacco products and marijuana regularly
- Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorptive syndrome, pancreatitis, gallbladder or biliary disease
- Presence of gastrointestinal disorder or surgeries within the past year
- Consuming prescription or non-prescription drug, herbal or nutritional supplements known to affect blood glucose, appetite and/or any other outcomes of the study as per investigator's judgment
- Known to be pregnant or lactating, or planning on becoming pregnant in the next 12 months
- Irregular menstrual cycles (i.e., frequent missed cycles), menopausal or post- menopausal
- Breakfast skippers
- Currently trying to lose or gain weight and any weight gain or loss of at least 10 lbs in previous three months
- Known intolerance, sensitivity or allergy to dairy products (including milk and cheese)
- Consumption of powders/protein supplements
- Extreme dietary habits
- Excessive alcohol intake
- Restrained Eaters
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dairy-based Product 1
2% Cow's milk (Neilson, St-Laurent, Quebec)
|
Crossover design: participants received all treatment arms in a randomized order
|
|
Experimental: Dairy-based Product 2
Regular fat cheddar cheese (Armstrong, St-Laurent, Québec)
|
Crossover design: participants received all treatment arms in a randomized order
|
|
Experimental: Plant-based Product 3:
Vanilla Soy Beverage (Silk, Broomfield, Colorado)
|
Crossover design: participants received all treatment arms in a randomized order
|
|
Experimental: Plant-based Product 4
Vanilla Almond Beverage (Earth's Own, Vancouver, British Columbia)
|
Crossover design: participants received all treatment arms in a randomized order
|
|
Experimental: Plant-based Product 5
Plant-based Cheddar-Style Block (President' Choice, Brampton, Ontario)
|
Crossover design: participants received all treatment arms in a randomized order
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood glucose level
Time Frame: Starting at the beginning of each sessions (0 min, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 9 times.
|
Venous blood collection via catheter
|
Starting at the beginning of each sessions (0 min, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 9 times.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective appetite
Time Frame: Measured every 15-30 minutes up to 160 minutes]. A total of 9 times.
|
Quantifying appetite by using Visual Analogue Scales. Scored 0 to 100
|
Measured every 15-30 minutes up to 160 minutes]. A total of 9 times.
|
|
Change in plasma metabolic and gut hormones (insulin, c-peptide, glucagon-like 1 receptor, glucagon-like 2 peptide and gastric inhibitory polypeptide)
Time Frame: Starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 7 times.
|
Venous blood collection via catheter
|
Starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 7 times.
|
|
Change in plasma amino acid concentrations
Time Frame: Starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 7 times.
|
Venous blood collection via catheter
|
Starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 7 times.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: G. Harvey Anderson, PhD, University of Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MYC_AcuteDairy_2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Dairy and plant-based dairy beverages and solids
-
University of TorontoCompletedObesity | Type 2 Diabetes MellitusCanada
-
Else Nutrition GH LtdChildren's Hosptial of Colorado Aurora, Colorado, United States; Laina VTMSRecruiting
-
Laval UniversityRecruitingGut Microbiota | Bone Health | Body Composition Changes | Bone Metabolism | Metabolic Health | Body Weight ChangeCanada
-
Anglia Ruskin UniversityDanone Nutricia ResearchCompletedGastrointestinal Dysfunction | Amino Acid ChangeUnited Kingdom
-
Nutricia ResearchTerminatedInfant Growth | Parent and Infant User ExperienceNetherlands
-
University of Texas at AustinDairy Management Inc.CompletedHypertension | PrehypertensionUnited States
-
University of AarhusEnrolling by invitation
-
University of CopenhagenUniversity of Aarhus; APC Microbiome IrelandCompleted
-
Antonio Molina LopezUniversidad Europea de Madrid; Universidad Pablo de OlavideCompletedAthletic Performance Enhancement | Body Composition Optimization | Nutritional Supplementation in AthletesItaly
-
LactalisCompleted